Dr. Matthew Pink is Senior Director and Head of Business Development at Biodesix. He joined the Company in November 2020. Matthew has over 12 years of Business Development, licensing, and strategy experience in the life-sciences sector, with an academic background in Biology, having received his Ph.D. in Neuroscience from the University of Colorado.
Prior to joining Biodesix, Matthew served as U.S. Director of Research External Innovation and U.S. Director of Business Development, Licensing and Strategy at CSL Behring, a global therapeutics company with a portfolio of plasma-derived, recombinant protein, and cell and gene therapies. Prior to his work at CSL, Matthew spent time at the University of Pennsylvania and the University of Colorado, driving the commercialization of technologies emerging from academic research. Over his career, Matthew has led the successful negotiation and signature of over 100 agreements, including in-licensing and out-licensing agreements, revenue generating service agreements, and an acquisition agreement.
Matthew is also passionate about making a difference in the treatment of brain cancer. After losing his father to glioblastoma in 2013, Matthew and his family established the Madison Brain Tumor 5K, an annual charity run/walk held in Madison, WI to raise awareness and funding for glioblastoma research. All money raised is donated to the National Brain Tumor Society.